Radiopharm Theranostics (ASX:RAD) secured approval from the Data and Safety Monitoring Committee (DSMC) to proceed to the next dose in its first phase clinical trial for radiotherapeutic asset 177Lu-RAD204 in patients with PD-L1 positive advanced cancers, according to a Tuesday filing with the Australian bourse.
The DSMC confirmed the safety, pharmacokinetic, and biodistribution data of the first group of four patients treated with 30 millicurie of 177Lu-RAD204, allowing the study to continue without modifications, the filing said.
The second group will start at 60 millicurie of Lu177, expected to enroll by the middle of the year, and expand to multiple tumor types, according to the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。